Trial Profile

A Phase I Study of FT819 in Subjects With B-cell Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FT 819 (Primary) ; Bendamustine; Cyclophosphamide; Fludarabine; Interleukin-2
Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions
Acronyms Landmark
Sponsors Fate Therapeutics

Most Recent Events

11 Dec 2025 Actual Primary Completion date changed to 18 Jun 2025.
02 Aug 2024 Status changed from recruiting to active, no longer recruiting.
09 May 2024 According to a Fate Therapeutics media release, the Company has successfully completed dose escalation in its Phase 1 BCM study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com